Cystatin C and target organ damage in arterial hypertension


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. Characteristics of interrelations between serum cystatin C level and target organ damage in arterial hypertension. Methods. 94 patients with arterial hypertension (age 30 - 65 years) were included into the study. Body mass index (BMI), proteinuria, carotid intima-media thicknesss, serum cytstatin C levels were determined. Echocardiography and 24-hour blood pressure monitoring were performed. Results. Median serum cystatin C level was (і029,4 ng/ml [772; 1216], min - 350 ng/ml, maximum 2371,95 ng/ml). Serum cystatin C level was asscociated with age, obesity, stage of arterial hypertension, glomerula filtration rate, left ventricular mass myocardial index, carotid intima-media thickness. Conclusion. Serum cystatin C level is associated with target organ damage in arterial hypertension.

Full Text

Restricted Access

About the authors

A. P Rebrov

Email: andreyrebrov@yandex.ru

A. L Kuklina

References

  1. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. Hypertension 2003; 42:2: 1206-1252.
  2. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония 2000: ключевые аспекты диагностики, дифференциальной диагностики, профилактики, клиники и лечения. М., 2000; 71-92.
  3. Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular mobility and mortality. Nephrol Dial Transplant 2005; 20:6: 1048-1056.
  4. Segura J., Campo C., Gil P. et al. Development of Chronic Kidney Disease and Cardiovascular Prognosis in Essential Hypertensive Patients. J Am Soc Nephrol 2004; 15:6: 1616-1622.
  5. Valderrabano F., Gomes-Campdera F., Jones E. Hypertension as cause of end-stage renal disease: lessons from international registries. Kidney Int 1998; 68:12: 60-66.
  6. Резниченко Н.Е., Панфилова Е.Ю., Данковцева Е.Н. и др. Возможности использования цистатина С в кардиологии. Медицинский алфавит. Больница. 2009; 2: 23-26.
  7. Laterza O.F., Price C.P., Scott M. G. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707.
  8. Larsson A., Malm J., Grubb A. et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest. 2004;64:25-30.
  9. Bokenkamp A., Domanetzki M., Zinck R. et al. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics. 1998;101:875-881.
  10. Fliser D., Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37:79-83.
  11. Вельков В.В. Цистатин С: Новые возможности и новые задачи для лабораторной диагностики. (Часть 1). Клинико-лабораторный консилиум. 2010; 5: 23-31.
  12. Tonelle C. et al. Partial amino acid sequence of two forms of human postgamma globulin. Biochemical Biophysical Research Communications. 1979; 86(3): 613-619.
  13. Rawlings N.D., Barrett A.J. Evolution of proteins of the cystatin superfamily. Journal of Molecular Evolution. 1990; 30: 60- 71.
  14. Hall A. et al. Structural basis for the biological specificity of cystatin C. J Biological Chemistry. 1995; 270: 5115-5121.
  15. Brown W.M., Dziegielewska K.M. Friends and relations of the cystatin superfamily - new members and their evolution. Protein Science. 1997; 6: 5-12.
  16. Finney H., Newman D.J., Thakkar H. et al. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch. Dis. Child. 2000; 82 (1): 71-75.
  17. Filler G., Bцkenkamp A., Hofmann W. et al. Clin. Biochem. 2005;38 (1:1-8.
  18. Ognibene A., Mannucci E., Caldini A. et al. Cystatin C reference values and aging. Clin. Biochem. 2006;39(6):658-661.
  19. Croda-Todd M.T., Soto-Montano X.J. et al. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin. Biochem. 2007; 40 (13-14): 1084-1087.
  20. Köttgen A., Selvin E., Stevens L.A. et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008; 51(3):385-394.
  21. Диагностика и лечение артериальной гипертензии. //Национальные клинические рекомендации ВНОК. М:2008, с.23.
  22. Арутюнов Г.П., Оганезова Л.Г. Гиперфильтрация у больных артериальной гипертензией: результаты эпидемиологического исследования. Тер. арх. 2009; 8: 24-30.
  23. Оганезова Л.Г. Почечная функция у кардиологических больных: оптимальные методы оценки. Кардиология сегодня. 2012; 1:5.
  24. Вельков В.В. Цистатин С: Новые возможности и новые задачи для лабораторной диагностики. (Часть 2). Клинико-лабораторный консилиум. 2011; 1: 27-38.
  25. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226.
  26. Palatini P., Benetti E., Zanier A. et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension. Nephron Clin Pract. 2009; 113(4): 309-14.
  27. Naour N., Fellahi S., Renucci J.F. et al. Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity. Obesity (Silver Spring). 2009; 17(12): 2121-2126.
  28. Liu J., Sukhova G.K., Sun J.S. et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1359-1366.
  29. Lutgens S.P., Cleutjens K.B., Daemen M.J. et al. Cathepsin cysteine proteases in cardiovascular disease. Faseb J. 2007; 21: 3029-3041.
  30. Sukhova G.K., Wang B., Libby P. et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ. Res. 2005; 96: 368-375.
  31. Bengtsson E., To K., Hakansson T. et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2151-2156.
  32. Patel P.C., Ayers C.R., Murphy S.A. et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009; 2(2): 98-104.
  33. Moran A., Katz R., Smith N.L. et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail. 2008; 14(1):19-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies